What Is Trulicity?

1. The Short Answer

Trulicity is an injectable prescription medicine whose active ingredient is dulaglutide. The current DailyMed label identifies Trulicity as a GLP-1 receptor agonist.

The main U.S. label context is type 2 diabetes. DailyMed describes Trulicity as a medication used with diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The label also includes a cardiovascular-risk reduction indication for adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

The official Trulicity site states that Trulicity is for adults and children 10 years and older with type 2 diabetes to improve blood sugar, and it is also used in adults with type 2 diabetes to reduce the risk of major cardiovascular events in people with heart disease or multiple cardiovascular risk factors.

Trulicity is a specific dulaglutide brand; it is not a general nickname for weight-loss drugs, semaglutide products, or tirzepatide products.

2. What Is Dulaglutide?

Dulaglutide is the active ingredient in Trulicity. Dulaglutide belongs to the GLP-1 receptor agonist group, a medicine category designed around glucagon-like peptide-1 receptor signaling. For class background, see What Is a GLP-1?.

“GLP-1 receptor agonist” is a class description, not a brand name. NCBI Bookshelf’s GLP-1 comparison places dulaglutide and semaglutide in the GLP-1 receptor agonist family and separately describes tirzepatide as a dual GIP/GLP-1 receptor agonist. This distinction highlights why Trulicity, Ozempic, and Mounjaro are related but not identical.

The brand-versus-molecule split:

3. Why Is Trulicity Part of the GLP-1 Conversation?

Trulicity is part of the GLP-1 conversation because dulaglutide is a GLP-1 receptor agonist. Lilly announced FDA approval of Trulicity in 2014 as a once-weekly therapy for adults with type 2 diabetes, years before the recent surge in public attention around Ozempic, Wegovy, Mounjaro, and Zepbound.

Public use of “GLP-1” now often covers several different ideas at once: the natural hormone, the receptor, GLP-1 receptor agonist medicines, dual incretin medicines, diabetes brands, and weight-management brands.

Trulicity’s place in the conversation is specific. It is a dulaglutide product with a U.S. label for type 2 diabetes and defined cardiovascular-risk reduction, not general weight management.

For related molecule explainers, see What Is Semaglutide? and What Is Tirzepatide?.

4. Trulicity vs Ozempic and Wegovy

Trulicity, Ozempic, and Wegovy all appear in GLP-1 discussions, but the names point to different products. The primary distinction is the active ingredient: Trulicity contains dulaglutide, while Ozempic and Wegovy contain semaglutide.

The Ozempic DailyMed label centers on type 2 diabetes, with additional defined cardiovascular and kidney-related indications in adult type 2 diabetes populations. For a separate page on that brand context, see What Is Ozempic?.

Wegovy is also semaglutide, but the Wegovy DailyMed label has a different brand context, including chronic weight management. While they share an active ingredient, one molecule can have multiple brand labels for different uses.

Naming and label comparison:

5. Trulicity vs Mounjaro and Zepbound

Trulicity and Mounjaro are both Lilly brands for type 2 diabetes, but they contain different active ingredients. Trulicity contains dulaglutide. Mounjaro contains tirzepatide.

Trulicity’s label describes dulaglutide as a GLP-1 receptor agonist. The Mounjaro DailyMed label describes tirzepatide as a dual GIP and GLP-1 receptor agonist. For a separate explanation, see What Is Mounjaro?.

Zepbound adds another layer. It shares the tirzepatide active ingredient with Mounjaro, but the Zepbound DailyMed label has a distinct brand label focused on weight management.

To avoid confusion, note these three details before comparing products:

• Brand: Trulicity, Mounjaro, or Zepbound.
• Active ingredient: Dulaglutide or tirzepatide.
• Receptor description: GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.

6. What About Cardiovascular-Risk Reduction?

Cardiovascular-risk reduction is included in Trulicity’s current U.S. label. DailyMed states that Trulicity is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Lilly announced the FDA cardiovascular-risk reduction approval in February 2020. This approval history explains why older articles may discuss Trulicity as more than a blood-sugar-only brand.

However, this cardiovascular indication is tied specifically to adults with type 2 diabetes in defined risk groups; it is not a general preventative claim for everyone.

7. Navigating Trulicity Comparisons

Confusion often arises when class, molecule, and label questions are mixed. For example, “Is Trulicity a GLP-1?” is a class question. “Is it the same as Ozempic?” is an active-ingredient question. “Is it for weight loss?” is a label-context question.

The factual distinctions are clear: Trulicity is a GLP-1 receptor agonist brand; it contains dulaglutide; it is different from semaglutide and tirzepatide products; and its U.S. label is centered on type 2 diabetes with a defined cardiovascular-risk reduction context.

Decisions about switching or starting medications depend entirely on individual health history, side effects, treatment goals, and prescribing clinician guidance.

8. Trulicity FAQ

• What is Trulicity in simple terms?

  Trulicity is the Lilly brand name for dulaglutide injection. The current U.S. label describes it as a once-weekly GLP-1 receptor agonist used with diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes mellitus.

• Is Trulicity the same thing as dulaglutide?

  No. Dulaglutide is the active ingredient, while Trulicity is the brand name. The distinction matters because brand names, active ingredients, labels, and patient instructions are not the same kind of information.

• How is Trulicity different from Ozempic?

  Trulicity contains dulaglutide and Ozempic contains semaglutide. Both are GLP-1 receptor agonist products associated with type 2 diabetes, but they are different active ingredients with separate U.S. labels.

• How is Trulicity different from Mounjaro?

  Trulicity contains dulaglutide and is described as a GLP-1 receptor agonist. Mounjaro contains tirzepatide and is described as a GIP and GLP-1 receptor agonist. They are different molecules and different brand labels.

9. Sources